Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Multicentre phase II trial of near-infrared imaging in elective colorectal surgery.

Ris F, Liot E, Buchs NC, Kraus R, Ismael G, Belfontali V, Douissard J, Cunningham C, Lindsey I, Guy R, Jones O, George B, Morel P, Mortensen NJ, Hompes R, Cahill RA; Near-Infrared Anastomotic Perfusion Assessment Network VOIR.

Br J Surg. 2018 Sep;105(10):1359-1367. doi: 10.1002/bjs.10844. Epub 2018 Apr 16.

2.

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

Gómez HL, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowski H, Nerón Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capó A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH.

Clin Breast Cancer. 2016 Feb;16(1):38-44. doi: 10.1016/j.clbc.2015.10.005. Epub 2015 Nov 10.

3.

Near-infrared laparoscopic fluorescence to guide fascial plane identification in total mesorectal excision for rectal cancer: A Video Vignette.

Ismael G, Al Furajji H, Cahill RA.

Colorectal Dis. 2015 Oct;17 Suppl 3:36. doi: 10.1111/codi.13089. No abstract available.

PMID:
26394742
4.

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G.

Ann Oncol. 2015 Feb;26(2):320-5. doi: 10.1093/annonc/mdu524. Epub 2014 Nov 17.

PMID:
25403587
5.

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart M, Awada A.

J Chemother. 2013 Aug;25(4):239-46. doi: 10.1179/1973947813Y.0000000085.

PMID:
23906077
6.

Planning cancer control in Latin America and the Caribbean.

Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G.

Lancet Oncol. 2013 Apr;14(5):391-436. doi: 10.1016/S1470-2045(13)70048-2.

PMID:
23628188
7.

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C.

Lancet Oncol. 2012 Sep;13(9):869-78. doi: 10.1016/S1470-2045(12)70329-7. Epub 2012 Aug 9.

PMID:
22884505
8.

Novel cytotoxic drugs: old challenges, new solutions.

Ismael GF, Rosa DD, Mano MS, Awada A.

Cancer Treat Rev. 2008 Feb;34(1):81-91. Epub 2007 Oct 1. Review.

PMID:
17905518
9.

Molecular-targeted therapies: lessons from years of clinical development.

Rosa DD, Ismael G, Lago LD, Awada A.

Cancer Treat Rev. 2008 Feb;34(1):61-80. Epub 2007 Sep 10. Review.

PMID:
17826917
10.

Trastuzumab (herceptin) for early-stage breast cancer.

Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M.

Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. Review.

PMID:
17512447
12.

Current management of ovarian carcinosarcoma.

Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, Piccart M, Awada A.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):316-24. Review.

PMID:
17362309
13.

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V.

Cancer Treat Rev. 2007 Feb;33(1):64-77. Epub 2006 Nov 17. Review.

PMID:
17113234
14.

OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.

Rosa DD, Ismael GF, de Azambuja E, Braga S, Cardoso F, Bleiberg H.

J Clin Oncol. 2006 Nov 10;24(32):5176-7; author reply 5177. No abstract available.

PMID:
17093286
15.

Molecular profiling of a tumor of unknown origin.

Ismael G, de Azambuja E, Awada A.

N Engl J Med. 2006 Sep 7;355(10):1071-2. No abstract available.

PMID:
16957161
16.

Clinical pattern of seizures in hospitalized children.

Dad MI, Ismael GA, Al-Oufi AA, Al-Mohammadi AH.

Neurosciences (Riyadh). 2003 Apr;8(2):107-9.

PMID:
23649027

Supplemental Content

Loading ...
Support Center